title: The role of constitutively activated STAT3 in B16 melanoma cells.
abstract: Constitutively activated STAT3 is found frequently in a wide variety of human tumors, including melanoma. Moreover, constitutive STAT3 activation actively participates in tumor formation and progression, making STAT3 an attractive target for cancer therapy. We report here that in murine B16 melanoma cells, which have been previously shown to express constitutively active STAT3, the expression of a mutant form of STAT3 with the canonical tyrosine phosphorylation site (residue 705) mutated to phenylanaine has dominant-negative properties (STAT3-DN). STAT3-DN inhibits STAT3 tyrosine phosphorylation and STAT3-dependent DNA binding activity. Most importantly, STAT3-DN expression in B16 cells inhibits their invasiveness, as well as their melanogenesis by down-regulation of tyrosinase mRNA and protein expression as well as tyrosinase activity. These results suggest that STAT3 signaling plays a critical role in regulating melanoma behavior, and may represent a druggable target for melanoma therapy.
authors.affiliation: Department of Pathology and Laboratory Medicine, University of Tennessee Health Science Center and the Center for Cancer Research, Memphis, TN, USA.
authors.forename: Chuan He
authors.initials: CH
authors.lastname: Yang
authors.forename: Meiyun
authors.initials: M
authors.lastname: Fan
authors.forename: Andrzej T
authors.initials: AT
authors.lastname: Slominski
authors.forename: Junming
authors.initials: J
authors.lastname: Yue
authors.forename: Lawrence M
authors.initials: LM
authors.lastname: Pfeffer
references.citation: J Biol Chem. 1996 Apr 5;271(14):8057-61
references.pmid: 8626489
references.citation: Curr Opin Cell Biol. 2001 Apr;13(2):211-7
references.pmid: 11248555
references.citation: Cell Mol Life Sci. 1999 Sep;55(12):1559-67
references.pmid: 10526573
references.citation: Mol Cell Biol. 1998 May;18(5):2553-8
references.pmid: 9566875
references.citation: Oncogene. 2000 May 15;19(21):2474-88
references.pmid: 10851046
references.citation: Science. 1995 Jul 7;269(5220):81-3
references.pmid: 7541555
references.citation: Immunity. 1999 Jan;10(1):105-15
references.pmid: 10023775
references.citation: Oncogene. 2000 May 15;19(21):2607-11
references.pmid: 10851059
references.citation: J Investig Dermatol Symp Proc. 1999 Sep;4(1):24-8
references.pmid: 10537003
references.citation: Science. 1997 May 30;276(5317):1418-20
references.pmid: 9162009
references.citation: Blood. 2001 May 1;97(9):2846-53
references.pmid: 11313280
references.citation: Cancer. 2002 Oct 15;95(8):1663-72
references.pmid: 12365014
references.citation: Oncogene. 2000 Dec 27;19(56):6613-26
references.pmid: 11426647
references.citation: J Cell Sci. 1988 Mar;89 ( Pt 3):287-96
references.pmid: 3143738
references.citation: Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3801-4
references.pmid: 9108058
references.citation: Cell. 1994 Apr 8;77(1):63-71
references.pmid: 7512451
references.citation: J Clin Invest. 1998 Oct 1;102(7):1385-92
references.pmid: 9769331
references.citation: Oncogene. 2002 Oct 10;21(46):7001-10
references.pmid: 12370822
references.citation: J Biol Chem. 1996 May 31;271(22):13221-7
references.pmid: 8675499
references.citation: Physiol Rev. 2004 Oct;84(4):1155-228
references.pmid: 15383650
references.citation: Mol Cell Biol. 1996 Apr;16(4):1595-603
references.pmid: 8657134
references.citation: J Biomed Sci. 1998;5(2):79-85
references.pmid: 9662066
references.citation: Cancer Res. 1999 Oct 15;59(20):5059-63
references.pmid: 10537273
references.citation: Science. 1994 Apr 1;264(5155):95-8
references.pmid: 8140422
references.citation: Oncogene. 2005 Aug 25;24(36):5552-60
references.pmid: 16007214
references.citation: Am J Physiol Cell Physiol. 2000 Feb;278(2):C331-5
references.pmid: 10666028
references.citation: Cancer Res. 1991 Nov 1;51(21):5881-7
references.pmid: 1718587
references.citation: J Biol Chem. 2002 Apr 26;277(17):15132-41
references.pmid: 11830592
references.citation: Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9097-101
references.pmid: 7568080
references.citation: Anticancer Res. 1998 Sep-Oct;18(5B):3709-15
references.pmid: 9854482
references.citation: Oncogene. 2000 May 15;19(21):2496-504
references.pmid: 10851048
references.citation: Proc Natl Acad Sci U S A. 1998 May 12;95(10):5568-72
references.pmid: 9576923
references.citation: Oncogene. 2000 May 15;19(21):2577-84
references.pmid: 10851056
references.citation: Oncogene. 2000 May 15;19(21):2557-65
references.pmid: 10851054
references.citation: J Clin Invest. 2001 Feb;107(3):351-62
references.pmid: 11160159
references.citation: Histopathology. 2000 May;36(5):387-402
references.pmid: 10792480